Birol Emir

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11934410/publications.pdf

Version: 2024-02-01

430874 276875 1,790 45 18 41 h-index citations g-index papers 46 46 46 1780 docs citations all docs times ranked citing authors

#	Article	IF	Citations
1	Efficacy, Safety, and Tolerability of Pregabalin Treatment for Painful Diabetic Peripheral Neuropathy. Diabetes Care, 2008, 31, 1448-1454.	8.6	280
2	Efficacy of Donepezil on Behavioral Symptoms in Patients With Moderate to Severe Alzheimer's Disease. International Psychogeriatrics, 2002, 14, 389-404.	1.0	211
3	Efficacy of Donepezil on Maintenance of Activities of Daily Living in Patients with Moderate to Severe Alzheimer's Disease and the Effect on Caregiver Burden. Journal of the American Geriatrics Society, 2003, 51, 737-744.	2.6	189
4	Sensory profiles of patients with neuropathic pain based on the neuropathic pain symptoms and signs. Pain, 2014, 155, 367-376.	4.2	176
5	Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Family Practice, $2010,11,85.$	2.9	71
6	Relationship Between Pain Relief and Improvements in Patient Function/Quality of Life in Patients With Painful Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Treated With Pregabalin. Clinical Therapeutics, 2013, 35, 612-623.	2.5	65
7	Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2â [^] metastatic breast cancer in US real-world clinical practice. Breast Cancer Research, 2021, 23, 37.	5.0	65
8	A Comprehensive Drug Safety Evaluation of Pregabalin in Peripheral Neuropathic Pain. Pain Practice, 2015, 15, 47-57.	1.9	61
9	Pregabalin in the Treatment of Refractory Neuropathic Pain: Results of a 15-Month Open-Label Trial. Pain Medicine, 2008, 9, 1202-1208.	1.9	56
10	Time to Onset of Neuropathic Pain Reduction: A Retrospective Analysis of Data From Nine Controlled Trials of Pregabalin for Painful Diabetic Peripheral Neuropathy and Postherpetic Neuralgia. American Journal of Therapeutics, 2010, 17, 577-585.	0.9	49
11	Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature. Journal of Psychopharmacology, 2015, 29, 1047-1060.	4.0	47
12	Prediction of Pregabalin-Mediated Pain Response by Severity of Sleep Disturbance in Patients with Painful Diabetic Neuropathy and Post-Herpetic Neuralgia. Pain Medicine, 2014, 15, 661-670.	1.9	45
13	Development of responder definitions for fibromyalgia clinical trials. Arthritis and Rheumatism, 2012, 64, 885-894.	6.7	42
14	Analysis of repeated markers used to predict progression of cancer., 1998, 17, 2563-2578.		38
15	Characterizing and understanding body weight patterns in patients treated with pregabalin. Current Medical Research and Opinion, 2012, 28, 1027-1037.	1.9	31
16	Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability. Current Medical Research and Opinion, 2013, 29, 1223-1230.	1.9	28
17	Correlations between Fibromyalgia Symptom and Function Domains and Patient Global Impression of Change: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials of Pregabalin. Pain Medicine, 2011, 12, 260-267.	1.9	22
18	Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials. Journal of Pain Research, 2015, 8, 257.	2.0	22

#	Article	IF	CITATIONS
19	Treatment patterns and survival in metastatic castrationâ€sensitive prostate cancer in the US Veterans Health Administration. Cancer Medicine, 2021, 10, 8570-8580.	2.8	22
20	Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity. Journal of Clinical Medicine, 2021, 10, 200.	2.4	21
21	Pandemic-related declines in hospitalization for non-COVID-19-related illness in the United States from January through July 2020. PLoS ONE, 2022, 17, e0262347.	2.5	21
22	Comparison of diagnostic markers with repeated measurements: a non-parametric ROC curve approach., 2000, 19, 511-523.		19
23	Efficacy and safety of pregabalin in patients with spinal cord injury: a pooled analysis. Current Medical Research and Opinion, 2013, 29, 1675-1683.	1.9	18
24	Examining the Time to Improvement of Sleep Interference With Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy and Postherpetic Neuralgia. American Journal of Therapeutics, 2015, 22, 257-268.	0.9	17
25	Time to Improvement of Pain and Sleep Quality in Clinical Trials of Pregabalin for the Treatment of Fibromyalgia. Pain Medicine, 2015, 16, 176-185.	1.9	17
26	Temporal analysis of pain responders and common adverse events: when do these first appear following treatment with pregabalin. Journal of Pain Research, 2015, 8, 303.	2.0	13
27	Examining the Time to Therapeutic Effect of Pregabalin in Spinal Cord Injury Patients With Neuropathic Pain. Clinical Therapeutics, 2015, 37, 1081-1090.	2.5	13
28	Electronic medical record data to identify variables associated with a fibromyalgia diagnosis: importance of health care resource utilization. Journal of Pain Research, 2015, 8, 131.	2.0	12
29	Improvement in pain severity category in clinical trials of pregabalin. Journal of Pain Research, 2016, Volume 9, 779-785.	2.0	10
30	Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy. PLoS ONE, 2018, 13, e0207120.	2.5	10
31	Anticoagulation Treatment and Outcomes of Venous Thromboembolism by Weight and Body Mass Index: Insights From the Veterans Health Administration. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008005.	2.2	10
32	Pain relief and functional improvement in patients with neuropathic pain associated with spinal cord injury: an exploratory analysis of pregabalin clinical trials. Journal of Pain Research, 2016, 9, 405.	2.0	9
33	Predictive Modeling of Response to Pregabalin for the Treatment of Neuropathic Pain Using 6-Week Observational Data: A Spectrum of Modern Analytics Applications. Clinical Therapeutics, 2017, 39, 98-106.	2.5	9
34	Identification of a potential fibromyalgia diagnosis using random forest modeling applied to electronic medical records. Journal of Pain Research, 2015, 8, 277-88.	2.0	9
35	Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status. Advances in Therapy, 2021, 38, 5519-5533.	2.9	7
36	Pregabalin in Treatment-Refractory Fibromyalgia. Open Rheumatology Journal, 2010, 4, 35-38.	0.2	7

#	Article	IF	CITATIONS
37	Integrating data from randomized controlled trials and observational studies to predict the response to pregabalin in patients with painful diabetic peripheral neuropathy. BMC Medical Research Methodology, 2017, 17, 113.	3.1	6
38	Dose Titration of Pregabalin in Patients with Painful Diabetic Peripheral Neuropathy:ÂSimulation Based on Observational Study Patients Enriched with Data from Randomized Studies. Advances in Therapy, 2018, 35, 382-394.	2.9	6
39	Increasing access to erectile dysfunction treatment via pharmacies to improve healthcare provider visits and quality of life: Results from a prospective realâ€world observational study in the United Kingdom. International Journal of Clinical Practice, 2021, 75, e13849.	1.7	6
40	Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics. Expert Opinion on Pharmacotherapy, 2010, 11, 2275-2280.	1.8	5
41	Prior Opioid Use Does Not Impact the Response to Pregabalin in Patients With Fibromyalgia. Clinical Journal of Pain, 2016, 32, 555-561.	1.9	5
42	<p>Integrating Machine Learning With Microsimulation to Classify Hypothetical, Novel Patients for Predicting Pregabalin Treatment Response Based on Observational and Randomized Data in Patients With Painful Diabetic Peripheral Neuropathy</p> . Journal of Pragmatic and Observational Research, 2019, Volume 10, 67-76.	1.5	5
43	Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network. Current Oncology, 2022, 29, 1047-1061.	2.2	4
44	Assessing the Value of Time Series Real-World and Clinical Trial Data vs. Baseline-Only Data in Predicting Responses to Pregabalin Therapy for Patients with Painful Diabetic Peripheral Neuropathy. Clinical Drug Investigation, 2019, 39, 775-786.	2.2	3
45	Finite Mixture Models, a Flexible Alternative to Standard Modeling Techniques for Extrapolated Mean Survival Times Needed for Cost-Effectiveness Analyses. Value in Health, 2021, 24, 1643-1650.	0.3	2